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Abstract Purpose: In preparation
for a tight glycaemic control (TGC)
clinical trial we assessed the agree-
ment between methods used to
measure blood glucose in critically ill
children. Methods: Service evalua-
tion comparing blood gas and main
laboratory analysers with point-of-
care (POC) devices PCX, ACCU-
Chek and Hemocue. Results: Two
hundred forty-five samples from 157
children measured on 2–4 devices
provided 790 values. Marked varia-
tion was evident in glucose values
between devices, time between tests,
sample (whole blood/plasma) and
source; 39% of paired values had
[20% difference. The decision to
start insulin at 7 mmol/L differed
depending on the device used for 33%
of samples. At low glucose values
(\4 mmol/L), differences up to
1.8 mmol/L were evident. The blood
gas analyser read lower than all POC
models and the laboratory analyser
(less risk of undetected hypoglycae-
mia). An inverse relationship was
evident between haematocrit (Hct)
and glucose error using POC devices.
PCX values for samples with Hct
\30% were higher (85%), whereas
those for Hct values [38% were
lower (66%). Glycolysis occurred
during transfer of samples to the
laboratory. Using the PCX at the
bedside resulted in 0.5 mmol/L mean
difference higher than laboratory
values; locating the PCX in the lab-
oratory reduced this to 0.2 mmol/L.
Conclusions: Discrepancies
between measurements may mask
hypoglycaemia, and the potential
benefits of controlling hyperglyca-
emia may not be achieved. Variation
introduced by different devices,
sample or source may have led to
misclassification of treatment deci-
sions contributing to the conflicting
results of TGC studies.
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Introduction
Accurate glucose control is important in critical care and
may have influenced the outcome in tight glycaemic
control (TGC) studies. Neonates and young children may
be more vulnerable to the adverse effects of hypogly-
caemia [1, 2]; their safety depends on early, accurate
detection and management. Control of hyperglycaemia
within the normal range may improve outcomes, as
demonstrated in randomised controlled trials in critically
ill adults [3] and children [1].
In clinical practice, different devices and types of blood
sample are used to measure glucose. Glucose values are
known to be affected by interferences in the sample
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including extreme biochemistry parameters that are com-
mon in the critically ill [4]. Glucose metabolises faster in
samples with high haematocrit and infants due to their
larger mean cell volume [5]. Conversely, low haematocrit
can lead to higher glucose values depending on the device
[6–8], leading to over-treatment with insulin and risk of
masking hypoglycaemia. Blood gas analysers measure the
molality of glucose, whereas POC devices measure glucose
concentration in whole blood. There is an inherent differ-
ence of 18% in values between these methods, requiring
adjustment to plasma equivalent laboratory values [6–8].
We speculate that inaccuracies in glucose measure-
ments may have contributed to different TGC study
outcomes. This view has gained increasing support [9–
13]. A meta-analysis concluded that TGC was not asso-
ciated with significantly reduced mortality but was
associated with increased risk of hypoglycaemia [14]. The
method for measuring glucose was only described in
10/27 studies, and protocols allowed different samples
and devices to be used that may have led to insulin dosing
errors [9]. Vlasselaer’s paediatric study [1] and Van den
Berghe’s initial study [3] reduced mortality. Both speci-
fied arterial samples tested on blood gas analysers
(Radiometer) and were single-centre studies.
In preparation for a clinical trial in paediatric intensive
care (PICU) we conducted a series of evaluations of the
agreement between glucose values to achieve targeted
blood glucose and prevent undetected hypoglycaemia.
The aim of the study is to define the magnitude of inac-
curacies that occur in routine practice by comparing
different devices, the effect of glycolysis and haematocrit.
Methods
The PICU at Royal Liverpool Children’s NHS Foundation
Trust UK is a 23-bed regional unit admitting around 1,100
children per annum including neonates (28%) and cardiac/
general admissions. Additional tests were only performed
when surplus blood (0.2 mL) remained from clinically
indicated biochemistry or blood gas samples during
2007–2009. The study was registered with the Trust
Research Directorate as a service evaluation consistent
with National Research Ethics Service guidance [15].
Quality control was monitored by biochemists and
adhered to manufacturer device standards including daily
high and low control checks. The coefficient of variation
for the blood gas analyser and clinical chemistry analyser
was \2% at a range of glucose concentrations. The lab-
oratory clinical chemistry analyser measures plasma, but
all other devices measure whole blood (Table 1).
Series 1: Routine practice—precision PCX (Abbott)
point of care and main laboratory n = 95 (arterial
n = 65, capillary n = 13 and central venous n = 17)
The sample was measured on the PCX (POC) at the
bedside then reached the main laboratory by vacuum pod
system in lithium heparin bottles within 10–30 min (or by
hand occasionally, delayed[4 h). Peripheral venous lines
were not used.
Series 2 and 3 measured arterial samples on three POC
devices and the laboratory, then separate samples on three
POC devices with the blood gas analyser. To minimise
glycolysis, tests were commenced on all four devices
within 10 min by locating POC devices in the respective
laboratories.
Series 2: time controlled between tests—PCX, Accu-
Chek and Hemocue (whole blood) less laboratory
(plasma) values and the effect of haematocrit
(n = 100) Arterial samples had 0.2 mL whole blood
removed in the laboratory followed by immediate testing
on three POC devices. The remaining sample was cen-
trifuged (3 min, 9,000 rpm) followed by full biochemistry
analysis on the plasma. Hematocrit data was collected
Table 1 Device, enzymes and methods
Device Enzymes Device methods
Blood gas analyser (GAS), Rapid Lab
Co-oximeter 1265 (Siemens
NY, USA)
Glucose oxidase Direct biosensor electrochemical
amperometric technology;
filters interferences
Clinical chemistry analyser laboratory
(LAB), Architech 8000 (Abbott,
Illinois, USA)
Glucose hexokinase Spectrophotometer
Precision PCX plus point-of-care
(POC) Medisense (PCX) (Abbott
MA, USA)
Glucose dehydrogenase (GDH)
Nicotinamide adenine dinucleotide (NAD)
Electrochemical
Accu-Cheka Performa (ACCU) (POC)
(Roche, Mannheim, Germany)
Glucose dehydrogenase (GDH)
Pyrroloquine quinine (PQQ)
(test strips have been modified recently)
Electrochemical
Hemocue 201 (HEMO) (POC)
(Hemocue, Angelholm, Sweden)
Modified glucose dehydrogenase (GDH)
Nicotinamide adenine dinucleotide (NAD)
Haemolysis (saponin)
Spectrophotometer
a Test strips have been modified recently
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when a routine full blood count (Sysmex XE-2100) was
available within 1 h of biochemistry analysis.
Series 3: time controlled between tests—PCX, Accu-
Chek and Hemocue (whole blood) with the blood gas
analyser (whole blood) (n = 50) Arterial samples in
heparin-balanced syringes 0.3–0.5 mL (Siemens) were
processed on the blood gas analyser then tested immedi-
ately on three POC devices (Table 2).
Data analysis
Pairs of values were compared to demonstrate the varia-
tion produced by different methods; agreement therefore
does not equal accuracy. Laboratory values were used for
comparison but were not referred to as a gold standard, as
plasma is measured, whereas all other devices measure
whole blood and are affected by glycolysis.
Clarke error grid [16] zones A–E represent varying
degrees of clinical accuracy to identify when glucose error
could lead to a different clinical decision in diabetes (Fig. 1).
Bland and Altman’s [17] method for clinical measure-
ment determines the mean difference (bias) and crude 95%
limits of agreement (LOA) to provide a comparison between
pairs of devices; individual graphs (MS Excel 2007) are
provided in the Electronic Supplementary Material (ESM).
Kendall’s tau-b rank correlation coefficient was used to
determine the significance of variability and the magnitude
of the glucose value. Measurements were log-transformed
using natural logarithm to base e; the antilog was then used
to determine the 95% LOA relative to the glucose values
using Stata 10 (Stata Corp., College Station, Texas). Gly-
colysis was investigated by comparing the systematic mean
difference when samples were tested with then without time
delays between tests. The effect of haematocrit on glucose
error was analysed by linear regression.
To determine when different values would alter the
decision to start insulin at 7 mmol/L (1 mmol/L =
18 mg/dL), each pair of values from the same sample
were grouped as: (A) both\7 mmol/L, (B) mixed values
±7 mmol/L, or (C) both above 7 mmol/L (2 pairs with
differences \1 mmol/L variation were excluded).
Groups B and C contained at least one value[7 mmol/L,
providing the percentage of values leading to a different
decision to start insulin.
Results
Two hundred forty-five samples collected from 157
patients were tested on 2–4 devices, providing 790 values.
Wide variation in glucose estimates was evident
between the PCX and laboratory, particularly when
samples were taken from venous or capillary sources
(series 1). A high proportion of paired values had [20%
difference, as 39% of values fell outside zone A on the
Clarke error grid [16] (Fig. 1); 12% fell in zone D, clas-
sed as ‘a dangerous failure to detect and treat blood
glucose clinically’.
Agreement improved in series 2. Having controlled
the time between tests and limiting the sample source to
arterial lines, 97% of values fell within zone A and 3%
within zone B. Similarly, the mean difference between
PCX and laboratory values reduced from a positive bias
of 0.5 mmol/L in series 1 to 0.2 mmol/L in series 2
(Fig. 2). A subset of samples in series 1 (n = 65) taken
from arterial lines showed closer agreement (95% LOA
-1.0 to 2.0 mmol/L) than when venous and capillary
samples were included (95% LOA -1.7 to 3.0 mmol/L).
Even at low blood glucose values (\4 mmol/L), dif-
ferences up to 1.8 mmol/L (series 1, Fig. 2) were evident.
The natural scale was compared with the log-transformed
data and antilog LOA for series 1–3 (ESM Table 1). The
PCX and Accu-Chek demonstrated a relationship between
difference and magnitude, but this was corrected by log
transformation. The Hemocue appeared to produce little
relationship between error and magnitude but had the
widest potential difference when compared with the GAS.
Table 2 Series of evaluations for blood glucose values
Series Samples, n Total
values, n
Blood glucose devices
Laboratory Blood gas PCX Accu-Chek Hemocue
Series 1: Routine practice
PCX point of care located in PICU less main
laboratory (arterial/capillary/venous)
95 190 H H
Three point-of-care models: PCX, Accu-Chek and
Hemocue, located in each laboratory to minimise
glycolysis by controlling the time between
tests (arterial samples)
Series 2: three POC devices less
laboratory ? haematocrit effect
100 400 H H H H
Series 3: three POC devices less blood gas
located in PICU (GAS)
50 200 H H H H
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Variation between values when the same sample was
measured on all four devices is summarised in Fig. 3; the
mean and crude 95% LOA are plotted to illustrate trends
(individual Bland–Altman plots are provided in ESM
Figs. 1-5). The mean difference between all three POC
devices was consistently higher when compared with the
GAS (mean PCX 0.8 mmol/L, Accu-Chek 0.04 mmol/L
and Hemocue 0.6 mmol/L) than with the laboratory (PCX
0.2 mmol/L, Accu-Chek -0.4 mmol/L and Hemocue
0 mmol/L). Similarly, the Accu-Chek read lower than
other POC devices and had closest agreement with the
GAS (series 3). In contrast, the PCX produced higher
values than other POC devices, laboratory and GAS.
Although the Hemocue had close agreement with labo-
ratory values, it produced wide variation from the GAS.
Low haematocrit produced higher glucose values on
POC devices (whole blood) compared with the laboratory
(plasma). The inverse relationship between glucose error
and haematocrit is illustrated by the subset of the lowest
(n = 21) haematocrit values: 85% read higher on the
PCX, in contrast to the highest haematocrit values
(n = 21), of which 66% read lower (series 2, Fig. 4).
Regression analysis confirmed the inverse relationship
between glucose error and haematocrit for the PCX
(P = 0.004, R2 = 0.082) and the Accu-Chek (P = 0.003,
Fig. 2 Bland–Altman plots comparing the agreement between
blood glucose values (mmol/L) from arterial samples measured in
the main laboratory with point-of-care PCX based in PICU
(series 1, n = 65), then with PCX located in the laboratory to
control the time between tests (series 2, n = 100)
Fig. 3 Comparison of agreement in blood glucose values between
pairs of devices; mean and crude 95% limits of agreement are
plotted to illustrate trends. The same sample was measured on three
point-of-care (POC) devices (PCX, Accu Chek and Hemocue) and
by the laboratory (series 2), then a different sample on three POC
devices and the blood gas analyser (series 3). Time between tests
was controlled to minimise glycolysis
Fig. 1 Clarke error grid illustrating the difference in glucose values
that can arise during routine practice and effect on clinical
decisions by comparing the PCX point of care to laboratory blood
glucose values (mmol/L) for arterial, venous and capillary samples
(n = 95, series 1)
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R2 = 0.084). Hemocue values did not show an inverse
effect (P = 0.28, R2 = 0.012). These data have relatively
poor correlation (ESM Figs. 6–8).
The decision to start insulin at 7 mmol/L would have
altered due to the differences in values for 33% of the
pairs of samples depending on which method was used in
a TGC protocol. Each sample in series 1 (n = 95) pro-
duced a pair of values for the PCX (POC) and laboratory,
of which 60 pairs were consistently \7 mmol/L
(group A), 11 pairs were mixed values ±7 mmol/L
(group B) (2 pairs\1 mmol/L difference were excluded)
and 22 pairs were consistently [7 mmol/L (group C).
Groups B and C included one value [7 mmol/L in each
pair that would trigger insulin, and 33% (11/33) of these
pairs produced mixed values above and below 7 mmol/L.
Discussion
Glucose concentration estimates vary when different
methods are used in clinical practice, which may mask
hypoglycaemia and influence decisions to control hyper-
glycaemia. Inconsistent measurements between devices
would lead or would have led to different ranges being
targeted, and the resulting clinical decisions lead to mis-
classification of data, making it difficult to distinguish
between the control and intervention group, particularly
in multicentre trials. These data show that the glucose
value is dependent on many factors, including device
standards and methods (including enzymes utilised in the
method), which are influenced by the blood sample,
haematocrit and glycolysis.
This evaluation has shown consistent variation between
each device or sample source. As a result a different deci-
sion to start insulin at 7 mmol/L would have been made for
33% of the paired samples and suggests this degree of error
may occur with each adjustment of insulin. Although trends
are evident, the values are affected by other factors,
therefore not sufficiently consistent to apply a constant
adjustment. PCX values are higher than the Accu-Chek and
GAS, and the Hemocue had close agreement with the lab-
oratory but poor agreement with the GAS. Agreement was
closer between all three POC and laboratory values than
with GAS values (Fig. 3), which may suggest that the GAS
reads lower than the laboratory or that variation diminished
after a longer period of glycolysis. Direct comparison
between the laboratory and a blood gas analyser with both
in the laboratory is required. Arterial samples have been
shown to be more reliable; venous blood may be contami-
nated by glucose infusions, producing a different
concentration throughout the sample, and capillary samples
may be affected by poor perfusion [4, 18].
POC devices are not designed to adjust to the extreme
clinical variables that occur in PICU or to achieve the level
of precision essential to implement a TGC protocol [9]. ISO
standards allow wider variation for POC devices (20%)
than for laboratories (10%) [19]. To achieve correct insulin
dosing 95% of the time requires the bias and coefficient of
variation (CV) of the meter to be\2%; a 10% total error led
to 16–45% insulin dose errors [20]. The College of Amer-
ican Pathologists found wide variation between the CV of
glucose meters (12–14%) and bias of as much as 41%,
considerably higher than for laboratories CV 2.5–4.3% and
bias\11%, (cited by [9, 13]).
Most glucose values fell in the normal range
(5–7 mmol/L) for both the control and intervention group;
at 7 mmol/L, 20% variation would result in a range of
values between 5.6 and 8.4 mmol/L, therefore data will
overlap. In series 1, 39% of pairs of samples had [20%
difference. In TGC, the intervention group targets glucose
below 7 mmol/L, but the control group data are also often
below 7 mmol/L and only occasionally between 7 and
12 mmol/L. As a result, a clinical trial using different
devices or sources is unlikely to generate data that
accurately represent the control and intervention group to
determine outcomes. Measurements generated by a single
device with a consistent bias would allow comparison of
the control and intervention group (even though it may
not be accurate). This may explain why single-centre
studies using single devices observed a reduction in
mortality [1, 3]. In contrast, the NICE Sugar Study did not
demonstrate improved outcomes; the protocol did not
specify the device to be used in the 41 centres [21].
Devices that over-estimate glucose levels may mask
hypoglycaemia; studies have been stopped due to safety
[22–24]. TGC substantially increases the risk of hypogly-
caemia reported as 25% in paediatrics [1], 5% in adult
surgical [3] and 18.7% in adult medical studies [25], com-
pared with 2.3% in children in PICU not receiving insulin
[26]. The ISO standard for POC allows ± 0.83 difference at
low values\4 mmol/L; this would allow a range between
1.37 and 3.03 for hypoglycaemia at 2.2 mmol/L [20].
Fig. 4 Difference in blood glucose values for samples with
extreme haematocrit values measured on the PCX point-of-care
device less laboratory values (mmol/L) for blood samples with
haematocrit below 30% compared with samples with haematocrit
above 38% (series 2)
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Undetected hypoglycaemia may have adverse conse-
quences that outweigh the benefits of TGC and, given the
use of different devices in some of the main TGC trials, may
have contributed to adverse study outcomes.
Low haematocrit may lead to higher glucose values,
depending on the device. Glucose concentration is higher in
plasma, as it dissolves in the aqueous part of the sample and
plasma has higher water content (0.93) than erythrocytes
(0.71) and whole blood (0.84), corresponding to a ratio of
plasma to whole blood of 1.11 [7]. The IFCC standard
requires a constant adjustment factor of 1.11 to convert
whole-blood concentration to plasma equivalent values on
POC devices [8]. This ratio does not then readjust to the
wide range of haematocrit the wide range of haematocrit
(24–53%) in PICU (series 2), resulting in an inverse rela-
tionship between haematocrit and glucose error. A change
in haematocrit from 0.4 to 0.7 will change the ratio from 1.1
to 1.38, an error of 26% [6]. The GAS analyser is not
affected by haematocrit, as it measures molality of glucose
(glucose per unit water mass) rather than concentration
(glucose quantity per unit volume). The difference between
the molality value on a GAS analyser (0.99) and glucose
concentration on POC (0.84) is 18% (0.99/0.84); as such
both devices require a constant adjustment to plasma
equivalent laboratory values (0.93) [7].
An individual value that over-estimates the level of
glucose is more important clinically than the combined
statistical effect. A child with 24% haematocrit had glu-
cose levels of 7.4 mmol/L PCX, 5.5 mmol/L laboratory
and 5.6 mmol/L GAS; insulin would have been started
based on the PCX result (series 1). Multiple factors
contribute to this variation, but these data suggest caution
with haematocrit\30%, as glucose values may be higher
on POC, leading to over-treatment with insulin or mask-
ing of hypoglycaemia. The inverse relationship between
haematocrit and glucose error for the PCX and the Accu-
Chek shown by regression analysis had relatively poor
correlation (also with quadratic regression), which may be
explained by the co-existence of other interferences that
increase or decrease values simultaneously.
POC devices use different enzymes and methods
known to be influenced by interferences in the sample
from substances that often co-exist in intensive care,
including high bilirubin, hyperlipidaemia, paracetamol,
uric acid, maltose, galactose and high and low oxygen
saturation [4]. Tang et al. [27] found, at high glucose
concentrations, that low pH decreased and high pH
increased blood glucose. The GAS analyser is specifically
designed for intensive care and uses reference and inter-
ference measuring electrodes to minimise the effect of
common interfering substances.
Laboratory values were lower due to glycolysis that
occurred during transfer. The positive bias of 0.5 mmol/L
(series 1) was initially interpreted as the PCX over-reading,
but reduced to 0.2 mmol/L (series 2) when controlling the
time between tests (Fig. 2). Sidebottom et al. [5]
demonstrated that glucose decreased more rapidly within
1 h for an infant (by 24%, Hct 0.81) possibly due to their
higher mean cell volume, compared with an adult (12.3%,
Hct 0.75). Posthouwer et al. [28] found that values
decreased by 0.2 mmol/L after 10 min and 0.6 mmol/L
after 60 min (P \ 0.01). Chan et al. [29] demonstrated that
glycolysis was similar in both fluoride oxalate (6.30 ± 1.21
mmol/L) and lithium heparin (6.32 ± 1.23 mmol/L) during
the first hour; after 4 h, fluoride oxalate had stabilised the
sample (6.12 ± 1.20 mmol/L), whereas lithium heparin
samples decreased (5.00 ± 1.19 mmol/L). These findings
suggest that standard hospital laboratory testing is not
suitable for glucose monitoring due to the time between
sampling and measurement, even with glucose inhibitors.
This evaluation strengthens the argument to stan-
dardise the device method and sample source in TGC
protocols. There may be advantages to using arterial
samples on blood gas analysers, as specified in the trials
that reduced mortality [1, 3]. Blood gas analysers in dif-
ferent centres use similar methodology, as opposed to the
diverse range utilised by different models of POC. Values
are provided quickly, allowing rapid protocol adjustments
and minimising glycolysis when based in PICU. They
minimise the effect of interfering substances and are
unaffected by haematocrit, reducing the risk of undetected
hypoglycaemia. Griesdale’s subgroup analysis demon-
strated improved outcomes for surgical patients [10]; Van
den Berghe suggests that this may be because surgical
patients are likely to have central venous access and
arterial samples measured on blood gas analysers [11]. In
contrast Van den Berghe’s study of medical patients did
not improve mortality and used a Hemocue POC device
and different sample sources [25].
A further study is required to compare agreement
between the blood gas analyser based in the laboratory and
the laboratory clinical chemistry analyser and between
blood gas analysers in participating centres before future
trials. This is troublesome, as they are not portable and
when located in the laboratory may not include a glucose
sensor. The Yellow Springs Instrument has been used as a
portable ‘gold standard’, but unless the sample is plasma
the value is affected by haematocrit [6]. The variation found
in this series would not be expected when using POC for
patients who are not exposed to extreme interferences such
as otherwise healthy diabetic patients. Agreement does not
equal accuracy but simply illustrates the variation that
occurs between methods in clinical practice.
Conclusions
Variation in blood glucose values due to different devices,
sample and source are evident when monitoring critically ill
children and risks masking hypoglycaemia. The potential
benefits of controlling hyperglycaemia are lost when
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variation between methods prevents consistent adherence to
glucose targets. The resulting misclassification of treatment
decisions may have led to different study outcomes, con-
tributing to the conflicting results of TGC studies. Future
studies should standardise the measurement techniques in
TGC protocols. The efficacy of TGC must be established
before the effectiveness of TGC can be truly assessed.
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